Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Boehringer Ingelheim
Daiichi Sankyo
Accenture
Johnson and Johnson
Cantor Fitzgerald
US Army
Deloitte
Cerilliant

Generated: October 22, 2018

DrugPatentWatch Database Preview

Tolmar Therap Company Profile

« Back to Dashboard

What is the competitive landscape for TOLMAR THERAP, and when can generic versions of TOLMAR THERAP drugs launch?

TOLMAR THERAP has four approved drugs.

There are ten US patents protecting TOLMAR THERAP drugs.

Summary for Tolmar Therap
US Patents:10
Tradenames:1
Ingredients:1
NDAs:4
Patent Litigation for Tolmar Therap: See patent lawsuits for Tolmar Therap

Drugs and US Patents for Tolmar Therap

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021731-001 Dec 14, 2004 RX Yes Yes 9,283,282 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021379-001 Jul 24, 2002 RX Yes Yes 9,283,282 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021379-001 Jul 24, 2002 RX Yes Yes 6,565,874 ➤ Try a Free Trial Y ➤ Try a Free Trial
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021488-001 Feb 13, 2003 RX Yes Yes 8,840,916 ➤ Try a Free Trial Y ➤ Try a Free Trial
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021379-001 Jul 24, 2002 RX Yes Yes 8,486,455 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Tolmar Therap

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021731-001 Dec 14, 2004 5,739,176 ➤ Try a Free Trial
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021731-001 Dec 14, 2004 5,278,201 ➤ Try a Free Trial
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021379-001 Jul 24, 2002 5,324,519 ➤ Try a Free Trial
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021731-001 Dec 14, 2004 RE37950 ➤ Try a Free Trial
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021488-001 Feb 13, 2003 RE37950 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Medtronic
UBS
Cipla
AstraZeneca
Johnson and Johnson
Mallinckrodt
McKinsey
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.